Trends in off-label β-blocker use: A secondary data analysis

Clinical Therapeutics

Volumn 28, Issue 10, 2006, Pages 1736-1746

  Lin, Hsiang Wen ^b   Phan, Kathy ^a   Lin, Swu Jane ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NONE

Author keywords

heart disease; National Ambulatory Medical Care Surveys (NAMCS); off label use, blockers

Indexed keywords

ACEBUTOLOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; ATENOLOL PLUS CHLORTALIDONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; BISOPROLOL FUMARATE; BISOPROLOL FUMARATE PLUS HYDROCHLOROTHIAZIDE; CARVEDILOL; LABETALOL; METOPROLOL SUCCINATE; NADOLOL; PROPRANOLOL; TIMOLOL MALEATE;

ADULT; AMBULATORY CARE; ANGINA PECTORIS; AORTA SUBVALVULAR STENOSIS; ARTICLE; CARDIOLOGIST; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DATA ANALYSIS; DEMOGRAPHY; DRUG INDICATION; ESSENTIAL TREMOR; FEMALE; HEALTH SURVEY; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL SPECIALIST; MIGRAINE; OFF LABEL DRUG USE; OUTPATIENT DEPARTMENT; PHEOCHROMOCYTOMA; PHYSICIAN; PRESCRIPTION; PRESCRIPTIVE AUTHORITY; PRIMARY MEDICAL CARE; TREATMENT INDICATION; TREND STUDY; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; DIAGNOSIS; DRUG UTILIZATION REVIEW; HUMANS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 33751555287     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.10.015     Document Type: Article

References (34)

1. Publication GAO/T-HEHS-96-212. US General Accounting Office. Prescription Drugs: Implications o f Drug Labeling and Off Label Use (1996), General Accounting Office, Washington, DC
2. Calfee J.E. The role of marketing in pharmaceutical research and development. PhamacoEconomics 20 Suppl 3 (2002) 77-85
3. Beck J.M., and Azari E.D. FDA, off-label use, and informed consent: Debunking myths and misconceptions. Food Drug Law J. 53 (1998) 71-104
4. Tabarrok A.T. Assessing the FDA via the anomaly of offlabel drug prescribing. Independent Rev 5 (2000) 25-53
5. Radley D.C., Finkelstein S.N., and Stafford R.S. Off-label prescribing among office-based physicians. Arch Intern Med 166 (2006) 1021-1026
6. Ufer M., Kimland E., and Bergman U. Adverse drug reactions and off-label prescribing for paediatric outpatients: A one-year survey of spontaneous reports in Sweden. Pharmacoepidemiol Drug Saf 13 (2004) 147-152
7. Neubert A., Dormann H., Weiss J., et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf 27 (2004) 1059-1067
8. Loder E.W., and Biondi D.M. Off-Label prescribing of drugs in specialty headache practice. Headache 44 (2004) 636-641
9. Sugarman J.H., Fleischer Jr. A.B., and Feldman S.R. Off-label prescribing in the treatment of dermatologic disease. J Am Acad Dermatol 47 (2002) 217-223
10. Ward R.M., Bates B.A., Benitz W.E., et al. Uses of drugs not described in the package insert (off-label uses). Pediatrics 110 (2002) 181-183
11. Choonara I., and Conroy S. Unlicensed and off-label drug use in children: Implications for safety. Drug Saf 25 (2002) 1-5
12. Available at:. Leading causes of death in the US. Centers for Disease Control and Prevention, National Center for Health Statistics. Accessed August 10, 2004 (2004). http://www.cdc.gov/nchs/fastats/Icod.htm
13. Ryan T.J., Antman E.M., Brooks N.H., et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Gardiol 34 (1999) 890-911
14. Adams Jr. K.F., Baughman K.L., Dec W.G., et al. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction: Pharmacological approaches. J Card Fail 5 (1999) 357-382
15. Pashos C.L., Normand S.L., Garfinkle J.B., et al. Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992. J Am Coll Cardiol 23 (1994) 1023-1030
16. Ryan T.I., and Melduni R.M. Highlights of latest American College of Cardiology and American Heart Association guidelines for management of patients with acute myocardial infarction. Cardiol Rev 10 (2002) 35-43
17. Physicians' Desk Reference Drug Guide for Mental Health Professionals (2002), Thomson Medical Economics, Montvale, NJ
18. Kennedy H.L. Current utilization trends for beta-blockers in cardiovascular disease. Am J Med 110 Suppl 5A (2001) 2S-6S
19. Unapproved drug uses. Knight Ridder Washington Bureau Web site (2004). http://161.188.204.190/krdigital/drug/
20. Available at:. US Dept of Health and Human Services Centers for Disease Control and Prevention. Public-Use Data Files (micro-data) (1973-2002). Accessed June 10 (2004). http://ftp.cdc.gov/pub/HealthStatistics/NCHS/Datasets/NAMCS/
21. Physicians' Desk Reference Drug Guide for Mental Health Professionals (1999), Thomson Medical Economics, Montvale, NJ
22. Physicians' Desk Reference Drug Guide for Mental Health Professionals (2000), Thomson Medical Economics, Montvale, NJ
23. Physicians' Desk Reference Drug Guide for Mental Health Professionals (2001), Thomson Medical Economics, Montvale, NJ
24. International Classification of Diseases. 9th Revision (2003-2004), Clinical Modification. http://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD9-CM/2003/
25. Publication GAO/PEMD 91-14. US General Accounting Office. Report: Off Label Drugs (1991), General Accounting Office, Washington, DC
26. Brosgart C.L., Mitchell T., Charlebois E., et al. Off-label drug use in human immunodeficiency virus disease. J Acquir Immune Defic Syndr Hum Retrovirol 12 (1996) 56-62
27. Chen H., Deshpande A.D., Jiang R., and Martin B.C. An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population. Pharmacoepidemiol Drug Saf 14 (2005) 629-638
28. Huang W.F., and Lai I.C. Patterns of sleeprelated medications prescribed to elderly outpatients with insomnia in Taiwan. Drug Aging 22 (2005) 957-965
29. Wang T.I., and Stafford R.S. National patterns and predictors of beta-blocker use in patients with coronary artery disease. Arch Intern Med 158 (1998) 1901-1906
30. Available at:. Medscape from WebMD. Metoprolol tartrate oral uses & dosage. Accessed October 10 (2004). http://www.medscape.com/druginfo/Druginf?id=1-210&name=METOPROLOL+TARTRA TE+ORAL&DrugType=1&MenuID=USEDOS&ClassID=N&GeneralStatement=N
31. The Wall Street Journal online. Health Care Poll-many people think that drugs should only be prescribed per FDA-approved use, not for off- label use (2004). http://www.harrisinteractive.com/news/newsletters/wsjhealthnews/WSJOnlin e_HI_Health-CarePoll2004vol3_shttp://www.harrisinteractive.com/news/news letters/wsjhealthnews/WSJOnline_HI_Health1.pdf
32. American Society of Hospital Pharmacists. ASHP statement on the use of medication for unlabeled uses. Am J Hosp Pharm 49 (1992) 2006-2008
33. Blackwell A.E., Beck J.M., and Dechert L.L.P. Drug manufacturers' First Amendment right to advertise and promote their products for off-label use: Avoiding a pyrrhic victory. Food Drug Law J 58 (2003) 439-462
34. Available at:. US Food and Drug Administration. "Off-Label" and investigational use of marketed drugs, biologics, and medical devices. Accessed September 17 (2001). http://www.fda.gov/oc/ohrt/irbs/off_label.html